Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Race and age disparities in receipt of sentinel lymph node biopsy for early-stage breast cancer.

Reeder-Hayes KE, Bainbridge J, Meyer AM, Amos KD, Weiner BJ, Godley PA, Carpenter WR.

Breast Cancer Res Treat. 2011 Aug;128(3):863-71. doi: 10.1007/s10549-011-1398-1. Epub 2011 Feb 22.

2.

Racial disparities in adoption of axillary sentinel lymph node biopsy and lymphedema risk in women with breast cancer.

Black DM, Jiang J, Kuerer HM, Buchholz TA, Smith BD.

JAMA Surg. 2014 Aug;149(8):788-96. doi: 10.1001/jamasurg.2014.23.

PMID:
25073831
3.

Disparities and trends in sentinel lymph node biopsy among early-stage breast cancer patients (1998-2005).

Chen AY, Halpern MT, Schrag NM, Stewart A, Leitch M, Ward E.

J Natl Cancer Inst. 2008 Apr 2;100(7):462-74. doi: 10.1093/jnci/djn057. Epub 2008 Mar 25.

PMID:
18364506
4.

Differential receipt of sentinel lymph node biopsy within practice-based research networks.

Meyer AM, Reeder-Hayes KE, Liu H, Wheeler SB, Penn D, Weiner BJ, Carpenter WR.

Med Care. 2013 Sep;51(9):812-8. doi: 10.1097/MLR.0b013e31829c8ca4.

5.

Surgeon specialization and use of sentinel lymph node biopsy for breast cancer.

Yen TW, Laud PW, Sparapani RA, Nattinger AB.

JAMA Surg. 2014 Feb;149(2):185-92. doi: 10.1001/jamasurg.2013.4350.

6.

Patterns of axillary surgical care for breast cancer in the era of sentinel lymph node biopsy.

Rescigno J, Zampell JC, Axelrod D.

Ann Surg Oncol. 2009 Mar;16(3):687-96. doi: 10.1245/s10434-008-0195-5. Epub 2008 Dec 20.

PMID:
19101768
7.

Disparities in receipt of lymph node biopsy among early-stage female breast cancer patients.

Halpern MT, Chen AY, Marlow NS, Ward E.

Ann Surg Oncol. 2009 Mar;16(3):562-70. doi: 10.1245/s10434-008-0205-7. Epub 2008 Nov 8.

PMID:
18998064
8.

Utilization of sentinel lymph node biopsy in patients with ductal carcinoma in situ undergoing mastectomy.

Shah DR, Canter RJ, Khatri VP, Bold RJ, Yang AD, Martinez SR.

Ann Surg Oncol. 2013 Jan;20(1):24-30. doi: 10.1245/s10434-012-2539-4. Epub 2012 Sep 28.

9.

Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs. SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from the SEER database.

Yi M, Giordano SH, Meric-Bernstam F, Mittendorf EA, Kuerer HM, Hwang RF, Bedrosian I, Rourke L, Hunt KK.

Ann Surg Oncol. 2010 Oct;17 Suppl 3:343-51. doi: 10.1245/s10434-010-1253-3. Epub 2010 Sep 19.

10.

Long-term morbidity of patients with early breast cancer after sentinel lymph node biopsy compared to axillary lymph node dissection.

Schulze T, Mucke J, Markwardt J, Schlag PM, Bembenek A.

J Surg Oncol. 2006 Feb 1;93(2):109-19.

PMID:
16425290
11.

Is sentinel lymph node biopsy more accurate than axillary dissection for staging nodal involvement in breast cancer patients?

Marrazzo A, Taormina P, Gebbiab V, David M, Riili I, Lo Gerfo D, Casà L, Noto A.

Chir Ital. 2007 Sep-Oct;59(5):693-9.

PMID:
18019642
12.

The interplay between hospital and surgeon factors and the use of sentinel lymph node biopsy for breast cancer.

Yen TW, Li J, Sparapani RA, Laud PW, Nattinger AB.

Medicine (Baltimore). 2016 Aug;95(31):e4392. doi: 10.1097/MD.0000000000004392.

13.

A longitudinal comparison of arm morbidity in stage I-II breast cancer patients treated with sentinel lymph node biopsy, sentinel lymph node biopsy followed by completion lymph node dissection, or axillary lymph node dissection.

Kootstra JJ, Hoekstra-Weebers JE, Rietman JS, de Vries J, Baas PC, Geertzen JH, Hoekstra HJ.

Ann Surg Oncol. 2010 Sep;17(9):2384-94. doi: 10.1245/s10434-010-0981-8. Epub 2010 Mar 11.

14.

Second biopsy of axillary sentinel lymph node for reappearing breast cancer after previous sentinel lymph node biopsy.

Intra M, Trifirò G, Viale G, Rotmensz N, Gentilini OD, Soteldo J, Galimberti V, Veronesi P, Luini A, Paganelli G, Veronesi U.

Ann Surg Oncol. 2005 Nov;12(11):895-9. Epub 2005 Sep 29.

PMID:
16195833
15.

Upstaging and improved survival of early breast cancer patients after implementation of sentinel node biopsy for axillary staging.

Vanderveen KA, Schneider PD, Khatri VP, Goodnight JE, Bold RJ.

Ann Surg Oncol. 2006 Nov;13(11):1450-6. Epub 2006 Sep 29.

PMID:
17009150
16.

Axillary sentinel lymph node biopsy after neoadjuvant chemotherapy for carcinoma of the breast.

Schwartz GF, Tannebaum JE, Jernigan AM, Palazzo JP.

Cancer. 2010 Mar 1;116(5):1243-51. doi: 10.1002/cncr.24887.

17.

Sentinel lymph node micrometastasis as a predictor of axillary tumor burden.

Dabbs DJ, Fung M, Landsittel D, McManus K, Johnson R.

Breast J. 2004 Mar-Apr;10(2):101-5.

PMID:
15009035
18.

Disparities in Use of Human Epidermal Growth Hormone Receptor 2-Targeted Therapy for Early-Stage Breast Cancer.

Reeder-Hayes K, Peacock Hinton S, Meng K, Carey LA, Dusetzina SB.

J Clin Oncol. 2016 Jun 10;34(17):2003-9. doi: 10.1200/JCO.2015.65.8716. Epub 2016 Apr 11.

19.

Long-term morbidity of sentinel node biopsy versus complete axillary dissection for unilateral breast cancer.

Crane-Okada R, Wascher RA, Elashoff D, Giuliano AE.

Ann Surg Oncol. 2008 Jul;15(7):1996-2005. doi: 10.1245/s10434-008-9909-y. Epub 2008 Apr 16.

PMID:
18415650
20.

Morbidity comparison of sentinel lymph node biopsy versus conventional axillary lymph node dissection for breast cancer patients: results of the sentinella-GIVOM Italian randomised clinical trial.

Del Bianco P, Zavagno G, Burelli P, Scalco G, Barutta L, Carraro P, Pietrarota P, Meneghini G, Morbin T, Tacchetti G, Pecoraro P, Belardinelli V, De Salvo GL; GIVOM.

Eur J Surg Oncol. 2008 May;34(5):508-13. Epub 2007 Jul 5.

PMID:
17614245

Supplemental Content

Support Center